Podium Presentations
Monday, June 2, 2014
2:15 PM - 3:15 PM
RESEARCH PODIUM PRESENTATIONS - SESSION I

2:15 PM - 3:15 PM
Room: Room 710a (7th Floor)
USA AFFORDABLE HEALTH CARE ACT STUDIES

AH1

2:15 PM - 2:30 PM

PROJECTING THE USE OF INPATIENT AND EMERGENCY DEPARTMENT SERVICES AFTER THE AFFORDABLE CARE ACT MEDICAID EXPANSION

Pickens G1, Carls G2, Eibner C3, Jiang HJ4, Karaca Z4, Weiss A1, Wong H4
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Ann Arbor, MI, USA, 3RAND Corporation, Arlington, VA, USA, 4Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA

AH2

2:30 PM - 2:45 PM

ESTABLISHING BENCHMARKS TO UNDERSTAND HOSPITAL UTILIZATION FOLLOWING MEDICAID EXPANSION UNDER THE AFFORDABLE CARE ACT

Weiss A1, Carls G2, Jiang HJ3, Karaca Z3, Pickens G1, Wong H3
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Ann Arbor, MI, USA, 3Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA

AH3

2:45 PM - 3:00 PM

ADJUSTING BUDGET IMPACT MODEL BASED ON NEW CHANGES DUE TO AFFORDABLE CARE ACT

Aggarwal S1, Topaloglu H2, Kumar S3
1Novel Health Strategies, Bethesda, MD, USA, 2NOVEL Health Strategies, Chevy Chase, MD, USA, 3GLOBAL ACCESS Monitor, Bethesda, MD, USA

AH4

3:00 PM - 3:15 PM

WILL THE AFFORDABLE CARE ACT (ACA) IMPROVE RACIAL/ETHNIC DISPARITY OF EYE EXAMINATION AMONG U.S. WORKING-AGE POPULATION WITH DIABETES?

Shi Q1, Fonseca V1, Zhao Y2, Krousel-Wood M1, Luo Q1, Shi L1
1Tulane University, New Orleans, LA, USA, 2College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, USA

2:15 PM - 3:15 PM
Room: Room 518abc (5th Floor)
COMPARATIVE EFFECTIVENESS RESEARCH STUDIES

CE1

2:15 PM - 2:30 PM

COMPARATIVE EFFECTIVENESS OF SMOKING CESSATION MEDICATIONS TO ATTENUATE WEIGHT GAIN FOLLOWING CESSATION

Yang M1, Wang X1, Chen H1, Johnson ML1, Essien EJ1, Peters RJ2, Abughosh S1
1University of Houston, Houston, TX, USA, 2University of Texas Health Science Center at Houston, Houston, TX, USA

CE2

2:30 PM - 2:45 PM

DETERMINING COMPARATIVE EFFECTIVENESS BENCHMARKS FOR EMERGING TREATMENTS FOR HEPATITIS C VIRUS (HCV) INFECTION IN THE SINGLE ARM STUDY DESIGN SETTING

Broglio K1, Quintana M1, Daar ES2, Kalsekar A3, Yuan Y3, Detry M1, Lewis R2, Le TK4, Berry S1
1Berry Consultants, LLC, Austin, TX, USA, 2Los Angeles Biomedical Research, Torrance, CA, USA, 3Bristol-Myers Squibb, Princeton, NJ, USA, 4Bristol-Myers Squibb, Hopewell, NJ, USA

CE3

2:45 PM - 3:00 PM

COMPARATIVE EFFECTIVENESS OF SURGERY AND DRUG THERAPY IN NEWLY DIAGNOSED PATIENTS WITH CAROTID ARTERY STENOSIS

Mehta DA, McCombs J
University of Southern California, Los Angeles, CA, USA

CE4

3:00 PM - 3:15 PM

ASSESSMENT OF COMPARATIVE EFFECTIVENESS RESEARCH METHODS GUIDANCE DOCUMENTS

McConeghy R1, Heinrich K2, Gatto N3, Caffrey A1
1University of Rhode Island, Kingston, RI, USA, 2Columbia University, New York, NY, USA, 3Pfizer, Inc, New York, NY, USA

2:15 PM - 3:15 PM
Room: Room 519ab (5th Floor)
MEDICAL DEVICE & DIAGNOSTIC RESEARCH STUDIES

MD1

2:15 PM - 2:30 PM

THE IMPACT OF MEDICAL DEVICE USE ON HOSPITAL COSTS

Ferguson M, Kim M, Patel P, Stockwell B
Boston Scientific, Natick, MA, USA

MD2

2:30 PM - 2:45 PM

COST-UTILITY OF TRANSCATHETER AORTIC VALVE IMPLANTATION COMPARED WITH SURGICAL AORTIC VALVE REPLACEMENT IN HIGH-RISK PATIENTS WITH SEVERE AORTIC STENOSIS: A PROSPECTIVE OBSERVATIONAL STUDY

Ribera A1, Ferreira-González I1, Slof J2, Cascant P1, Abdul-Jawad O1, Marsal JR1, Serra V1, Garcia del Blanco B1, Tornos P1, Sureda C1, Falces C3, Andrea R3, Gutiérrez E4, del Valle R5, Mota P6, Goicolea J7, Permanyer G1, Garcia-Dorado D1
1Vall d'Hebron University Hospital, Barcelona, Spain, 2Universitat Autonoma de Barcelona, Bellaterra, Spain, 3Hospital Clínic i Provincial de Barcelona, Barcelona, Spain, 4Instituto de Investigación Sanitaria Gregorio Maranon, Universidad Complutense, Madrid, Spain, 5Hospital Central de Asturias, Oviedo, Spain, 6Hospital Clínico de Valladolid, Valladolid, Spain, 7Hospital Puerta de Hierro/Majadahonda, Madrid, Spain

MD3

2:45 PM - 3:00 PM

ASSESSING WHETHER “BIG DATA” SOLUTIONS PROVIDE VALUE FOR DIAGNOSTICS MANUFACTURERS

Hertz D, Gavaghan M, Garfield S
GfK Market Access, Wayland, MA, USA

MD4

3:00 PM - 3:15 PM

REAL-WORLD COST EFFECTIVENESS OF THE MITRACLIP FOR THE TREATMENT OF HIGH-RISK MITRAL REGURGITATION

Asgar AW1, Khairy P1, Bernard L2, Cameron HL2, Ducharme A1, Guertin M1, Bonan R1, L'Allier P1, Tardif J1, Cohen D3
1Montreal Heart Institute, Montreal, QC, Canada, 2Cornerstone Research Group, Burlington, ON, Canada, 3Saint Lukes Hospital, Kansas City, KS, USA

2:15 PM - 3:15 PM
Room: Room 520ad (5th Floor)
RESEARCH ON MODELING METHODS STUDIES

MO1

2:15 PM - 2:30 PM

A UNIFIED FRAMEWORK FOR CLASSIFICATION OF METHODS FOR BENEFIT-RISK ASSESSMENT

Najafzadeh M1, Schneeweiss S1, Choudhry NK1, Bykov K1, Kahler K2, Martin D2, Arcona S2, Rogers JR1, Gagne JJ1
1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

MO2

2:30 PM - 2:45 PM

BENEFITS FROM INCORPORATING NETWORK META-ANALYSIS WITHIN STRATIFIED COST-EFFECTIVENESS ANALYSIS

Coyle D1, Coyle K2, Cameron C1, Lee KM3, Kelly S1, Steiner S4, Wells G5
1University of Ottawa, Ottawa, ON, Canada, 2Brunel University, Uxbridge, ON, Canada, 3Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada, 4Medical University Vienna, Vienna, Austria, 5University of Ottawa Heart Institute, Ottawa, ON, Canada

MO3

2:45 PM - 3:00 PM

POPULATION HEALTH MODEL: PROJECTING HEALTH TRAJECTORY OF THE MASSACHUSETTS POPULATION

Olchanski N1, Zhong Y1, Winn A2, Saret CJ1, Cohen JT3
1Tufts Medical Center, Boston, MA, USA, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA

MO4

3:00 PM - 3:15 PM

AN EMPIRICAL COMPARISON OF A MARKOV COHORT MODEL AND A DISCRETE EVENT SIMULATION FOR COST-EFFECTIVENESS ANALYSIS IN ORTHOPAEDICS

Standfield LB, Comans T, Scuffham PA
Griffith University, Meadowbrook, Australia

2:15 PM - 3:15 PM
Room: Room 520cf (5th Floor)
PATIENT PREFERENCE STUDIES

PP1

2:15 PM - 2:30 PM

PREFERENCES FOR PROSTATE CANCER OUTCOMES: A COMPARISON OF PATIENT AND GENERAL POPULATION PERSPECTIVES

Gries KS1, Regier DA2, Ramsey SD3, Patrick DL1
1University of Washington, Seattle, WA, USA, 2BC Cancer Agency, Vancouver, BC, Canada, 3Fred Hutchinson Cancer Research Center, Seattle, WA, USA

PP2

2:30 PM - 2:45 PM

MAXIMUM DIFFERENCE SCALING: A NOVEL TECHNIQUE FOR DETERMINING PATIENT PREFERENCES

Stephenson JJ1, Kern DM2, Wu B2, Tunceli O2, Rodriguez A2, Horne LN3, Sackeyfio A4, Mackillop N4
1HealthCore Inc, Wilmington, DE, USA, 2HealthCore, Inc., Wilmington, DE, USA, 3AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 4AstraZeneca, Alderley Park, UK

PP3

2:45 PM - 3:00 PM

HOW CANADIANS VALUE RARE DISEASES GIVEN THEIR OPPORTUNITY COST?

Rizzardo S, Bansback N, Mitton C, Marra C, Lynd L
University of British Columbia, Vancouver, BC, Canada

PP4

3:00 PM - 3:15 PM

PATIENT PREFERENCES OF TREATMENTS AMONG WOMEN WITH METASTATIC BREAST CANCER: RESULTS FROM A CONJOINT ANALYSIS STUDY

DiBonaventura M1, Copher R2, Basurto E1, Faria C2, Lorenzo R1
1Kantar Health, New York, NY, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA

2:15 PM - 3:15 PM
Room: Room 520be (5th Floor)
TREATMENT PATTERNS STUDIES

TP1

WITHDRAWN

TP2

2:15 PM - 2:30 PM

TREATMENT PATTERNS AMONG ELDERLY STAGE IV BREAST CANCER PATIENTS TREATED WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-TARGETED THERAPY: AN ANALYSIS OF 2006-2010 US NATIONAL REGISTRY DATA

Lang K1, Hao Y2, Huang H1, Lin I1, Rogerio JW2, Menzin J1
1Boston Health Economics, Inc., Waltham, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

TP3

2:30 PM - 2:45 PM

LONGITUDINAL RESOURCE USE FOR LOW BACK PAIN IN COMMERCIALLY-INSURED PATIENTS IN THE UNITED STATES

Bresnahan BW1, Rundell S1, Beck SJ2, Hansen RN3, Jarvik JG1, Sullivan SD1, Flum D4, Alfonso-Cristancho R4
1University of Washington, Seattle, WA, USA, 2University of Washington, Department of Surgery, Seattle, WA, USA, 3School of Pharmacy, University of Washington, Seattle, WA, USA, 4Department of Surgery, University of Washington, Seattle, WA, USA

TP4

2:45 PM - 3:00 PM

DESCRIPTIVE ANALYSIS OF TREATMENT PATTERNS AND MORTALITY OF U.S. VETERAN PATIENTS WITH COLORECTAL CANCER

Seal BS1, Xie L2, Rietschel P3, Baser O4
1Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, 2STATinMED Research, Ann Arbor, MI, USA, 3Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA, 4STATinMED Research and The University of Michigan, Ann Arbor, MI, USA
3:45 PM - 4:45 PM
RESEARCH PODIUM PRESENTATIONS - SESSION II

3:45 PM - 4:45 PM
Room: Room 519ab (5th Floor)
RESEARCH ON DATABASE METHODS STUDIES

DB1

3:45 PM - 4:00 PM

A COMPARISON OF REGRESSION AND STATISTICAL LINKAGE ESTIMATORS OF BIAS IN RETROSPECTIVE DATABASE STUDIES

Crown W1, Chang J1, Olson M2, Kahler K3, Buzinec P4
1Optum Labs, Cambridge, MA, USA, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4OptumInsight, Eden Prairie, MN, USA

DB2

4:00 PM - 4:15 PM

CONDITIONS OF VALIDITY OF MEDICAL RECORDS FOR DRUG EXPOSURE ASSESSMENT IN PHARMACOEPIDEMIOLOGICAL RESEARCH

Grimaldi-Bensouda L1, Rossignol M1, Aubrun E1, Benichou J2, Abenhaim L3
1LA-SER, Paris, France, 2CHU de Rouen, INSERM U657, Rouen, France, 3LA-SER, London, UK

DB3

4:15 PM - 4:30 PM

A SPATIAL DISTRIBUTION OF ADULT OBESITY PREVALENCE IN DENVER COUNTY, COLORADO: AN EMPIRICAL BAYES APPROACH

Tabano DC1, Barrow JC1, Daley MF2
1Kaiser Permanente, Denver, CO, USA, 2Kaiser Permanente Institute for Health Research, Denver, CO, USA

DB4

4:30 PM - 4:45 PM

THE APPLICATION OF NATURAL LANGUAGE PROCESSING (NLP) TECHNOLOGY TO ENRICH ELECTRONIC MEDICAL RECORDS (EMRS) FOR OUTCOMES RESEARCH IN ONCOLOGY

Hirst C1, Hill J2, Khosla S1, Schweikert K2, Senerchia C2, Kitzmann K2, Zhang Q1
1AstraZeneca, Macclesfield, UK, 2Humedica, Boston, MA, USA

3:45 PM - 4:45 PM
Room: Room 518abc (5th Floor)
HEALTH CARE POLICY STUDIES

HC1

3:45 PM - 4:00 PM

CADTH RECOMMENDATIONS AS PREDICTORS FOR DRUG AVAILABILITY IN BRITISH COLUMBIA AND ONTARIO

Liden D, Jaksa A, Daniel K, Ho Y
Context Matters, Inc., New York, NY, USA

HC2

4:00 PM - 4:15 PM

THE IMPACT OF NICE'S END-OF-LIFE THRESHOLD ON PATIENT ACCESS TO NEW CANCER THERAPIES IN ENGLAND AND WALES

Stewart G, Eddowes L, Hamerslag L, Kusel J
Costello Medical Consulting Ltd., Cambridge, UK

HC3

4:15 PM - 4:30 PM

INCENTIVIZING VALUE IN MANAGED CARE DRUG FORMULARIES: DESIGN, IMPLEMENTATION, AND FIRST-YEAR OUTCOMES OF A VALUE-BASED FORMULARY

Watkins J1, Sullivan SD2, Yeung K3, Ramsey S4, Garrison L2, Wong E1, Murphy C1, Danielson D1, Veenstra DL3, Vogeler C1, Burke W5, McGee R1
1Premera Blue Cross, Mountlake Terrace, WA, USA, 2School of Pharmacy, University of Washington, Seattle, WA, USA, 3University of Washington, Seattle, WA, USA, 4Fred Hutchinson Cancer Research Center and Professor, Department of Medicine, University of Washington, Seattle, WA, USA, 5School of Medicine, University of Washington, Seattle, WA, USA

HC4

4:30 PM - 4:45 PM

THE POTENTIAL IMPACT OF RECOMMENDATIONS MADE THROUGH THE COMMON DRUG REVIEW PROGRAM AT THE CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH

Agarwal A1, Coyle D2, Lee KM1
1Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada

3:45 PM - 4:45 PM
Room: Room 710a (7th Floor)
HEALTH TECHNOLOGY ASSESSMENT STUDIES

HT1

3:45 PM - 4:00 PM

RECENT HEALTH TECHNOLOGY ASSESSMENT DECISIONS ACROSS THE GLOBE: A FOCUS ON ONCOLOGY

Clark RS, Zagadailov E, Bramley T
Xcenda, Palm Harbor, FL, USA

HT2

4:00 PM - 4:15 PM

ASSESSING THE VALUE OF TREATMENTS FOR RARE DISEASES USING AN MCDA-BASED APPROACH: METHODOLOGICAL AND ETHICAL FOUNDATIONS OF CRITERIA SELECTION AND FRAMEWORK DEVELOPMENT

Wagner M1, Khoury H1, Willet J2, Rindress D1, Goetghebeur M1
1LASER Analytica, Montreal, QC, Canada, 2LASER Analytica, New York, NY, USA

HT3

4:15 PM - 4:30 PM

IDENTIFYING RECENT TRENDS IN HEALTH TECHNOLOGY ASSESSMENTS FOR CROHN'S DISEASE

Mahendraratnam N, Inocencio TJ, Gaffney J, Agatep BC, Hughes KE
Avalere Health LLC, Washington, DC, USA

HT4

4:30 PM - 4:45 PM

COST-EFFECTIVENESS REVIEWS BY HTA AGENCIES: A COMPARISON OF FACTORS LEADING TO UNFAVOURABLE REVIEWS FOR ONCOLOGY AGENTS

Smith N, Beckerman R
CBPartners, New York, NY, USA

3:45 PM - 4:45 PM
Room: Room 520ad (5th Floor)
MEDICATION ADHERENCE STUDIES

MA1

3:45 PM - 4:00 PM

NON-ADHERENCE IS ASSOCIATED WITH POORER HEALTH OUTCOMES AMONG WOMEN CURRENTLY TREATED FOR BREAST CANCER WITH ORAL ENDOCRINE THERAPY

Goren A1, Geynisman DM2
1Kantar Health, New York, NY, USA, 2Fox Chase Cancer Center Temple Health, Philadelphia, PA, USA

MA2

4:00 PM - 4:15 PM

NON-ADHERENCE TO ANTIPLATELET THERAPY AFTER HOSPITALIZATION FOR ACUTE CORONARY SYNDROME (ACS) INCREASES READMISSIONS, MORTALITY, HEALTH CARE USE AND COSTS

Hill J1, Pokras SM1, Makin C1, Schabert VF1, Nelson M2, Foody J3
1IMS Health, Plymouth Meeting, PA, USA, 2IMS Health, Alexandria, VA, USA, 3Brigham and Women’s Hospital, Boston, MA, USA

MA3

4:15 PM - 4:30 PM

ADHERENCE AND PATIENT REPORTED OUTCOMES IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING BIOLOGIC MEDICATIONS: ANALYSIS OF SPECIALTY PHARMACY PROGRAM DATA

Olvey EL1, Crowe M2, Chandanais R2, Nolan R2, Rice G2
1NucleusX Market Access, Atlanta, GA, USA, 2Diplomat Pharmacy, Flint, MI, USA

MA4

4:30 PM - 4:45 PM

SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF MEDICATION ADHERENCE WITH ONCE WEEKLY VERSUS ONCE DAILY THERAPY IN PATIENTS WITH OSTEOPOROSIS

Iglay K, Joshi K, Cao X, Mavros P, Tunceli K
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA

3:45 PM - 4:45 PM
Room: Room 520be (5th Floor)
RISK MANAGEMENT STUDIES

RI1

3:45 PM - 4:00 PM

PREDICTING THE RISK OF CLOSTRIDIUM DIFFICILE INFECTION UPON ADMISSION: A RISK SCORE TO IDENTIFY PATIENTS FOR PHARMACIST ANTIBIOTIC REVIEW AND EDUCATION

Smith DH, Kuntz JL, Petrik AF, Yang X, Thorp ML, Spindel SJ, Barton T, Barton K, Labreche M, Johnson ES
Kaiser Permanente Northwest, Portland, OR, USA

RI2

4:00 PM - 4:15 PM

WARFARIN DISCONTINUATION AND STROKE RISK AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

Wang J1, Qiao Y1, Spivey CA1, Liu X2, Phatak H3, Mardekian J4, Claflin AB4, Kachroo S3, Abdulsatter Y4, Parker RB1
1The University of Tennessee College of Pharmacy, Memphis, TN, USA, 2University of Tennessee, College of Pharmacy, New York, NY, USA, 3Bristol-Myers Squibb Company, Princeton, NJ, USA, 4Pfizer, Inc., New York, NY, USA

RI3

4:15 PM - 4:30 PM

DISPARITY IN HIGH RISK MEDICATION USE BETWEEN DUAL AND NON-DUAL ELIGIBLE MEDICARE ADVANTAGE BENEFICIARIES: A DECOMPOSITION ANALYSIS

Pulungan Z, Parente A, Mehta S, Jones B, Teigland C
Inovalon Inc., Bowie, MD, USA

RI4

4:30 PM - 4:45 PM

RISK FACTORS ASSOCIATED WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) BACTEREMIA IN THE UNITED STATES

Pawar AM, Willey CJ, Caffrey AR
University of Rhode Island, Kingston, RI, USA

3:45 PM - 4:45 PM
Room: Room 520cf (5th Floor)
UTILITY MEASUREMENT STUDIES

UT1

3:45 PM - 4:00 PM

EQ-5D: WHICH DIMENSION MATTERS MOST AMONG DIABETES PATIENTS

Dierick K1, Mcbride M2, Love T2, Dean C3, Pike I3, Herterich R4
1GfK Disease Atlas, Brussels, Belgium, 2GfK USA, New York, NY, USA, 3GfK NOP, London, UK, 4GfK, Nürnberg, Germany

UT2

4:00 PM - 4:15 PM

HEALTH STATE UTILITIES ASSOCIATED WITH ATTRIBUTES OF TREATMENTS FOR HEPATITIS C

Matza LS1, Sapra S2, Kalsekar A2, Dillon JF3, Davies E4, Devine MK1, Jordan J1, Landrian A1, Feeny DH5
1Evidera, Bethesda, MD, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3University of Dundee, Dundee, UK, 4Evidera, London, UK, 5University of Alberta, Portland, OR, USA

UT3

4:15 PM - 4:30 PM

ASSESSING FACTORS ASSOCIATED WITH SELF-REPORTED HEALTH STATUS IN THE UNITED STATES USING A STRUCTURAL EQUATION MODEL

Zhao Y, Gu NY
University of New Mexico, Albuquerque, NM, USA

UT4

4:30 PM - 4:45 PM

DEVELOPMENT AND VALIDATION OF AN APPROACH TO INTERPRET COMPUTERIZED ADAPTIVE TEST SCORES FOR ASSESSING PATIENT OUTCOMES

Sinha R1, Slavin MD1, Ni P1, Houlihan B1, Skeels SE2, Zazula J1, Jette A1
1Boston University School of Public Health, Boston, MA, USA, 2Tufts University, Medford, MA, USA
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.